^ ei)wµtñ ao ¶Yí iuýZéuñgÊ -...

14
나노물질 위해성 평가: 논점과 전망 1) 김 은 주* <> I. 배경 II. 나노물질의 제조 III. 나노물질의 노출 경로 IV. 나노물질의 독성 평가 . 나노물질 위해성평가 문제점 . 나노물질 위해성평가기술 발전 전망 I. 배경 최근 들어, 산업 각 분야에서 나노물질이라는 포괄적 의미의 용어 사용이 늘어나고 있다. 나노물질의 정의는 일반적으로 지름이 1~100nm인 입자 형태의 물질을 일컫는다. 그러나, 생명 체 내에 존재하는 단백질 등 고분자 물질 역시 인류 역사가 시작된 이래 나노크기로 존재하여 왔음에도, 이러한 나노물질의 범주에 포함되지 않는다. 따라서, “나노물질을 보다 구체적으로 정의 내려보면, 나노 크기(10 -9 m) 수준으로 물질의 제조, 제어 및 분석이 가능해 지면서 화학 및 바이오 산업 분야에 널리 사용되고 있는 제조나노물질로 정의할 수 있을 것이다. EU에서 규 정한 정의(EC 1123/2009)는 지금까지 정의된 유일한 법적 정의로서, “불용성 또는 생체 내에서 지속적이고, 의도적으로 제조된 것으로서, 하나 이상의 외부 치수 또는 내부구조가 1~100nm규모인 물질을 나노물질로 표시할 수 있다고 정의하고 있다. OECD에서 정한 우선연구대상 나노물질의 목록(<1>)을 보면, (Ag), 탄소나노튜브(C), (Fe), 이산화티타늄(TiO2), 산화알루미늄(AlO, Al2O3) 산화아연(ZnO), 이산화규소(SiO2), 폴리스티 렌 등 새로운 성분의 화합물이 아닌, 지금까지 다양하게 사용되어온 물질의 성분으로 구성되어 있음을 알 수 있다. 그럼에도 불구하고, 나노물질을 크기의 범주 하에 분리하여 고려하는 이유 , 나노물질이 보통 크기의 상대물질에 비해 상당히 다르게행동하는 것으로 밝혀지고 있기 * 대구경북과학기술원 나노바이오연구부

Transcript of ^ ei)wµtñ ao ¶Yí iuýZéuñgÊ -...

  • :

    1) *

    I.

    II.

    III.

    IV.

    .

    .

    I.

    , .

    1~100nm . ,

    , . ,

    , (10-9m) ,

    . EU

    (EC 1123/2009) ,

    , , 1~100nm

    .

    OECD () , (Ag), (C),

    (Fe), (TiO2), (AlO, Al2O3) (ZnO), (SiO2),

    ,

    . ,

    ,

    *

  • 194 49(2010)

    . ,

    , .

    , ,

    .

    .

    .

    ( ) ,

    .

    , ,

    ,

    (Khanna, 2008).

    (colloid) ,

    ,

    (Yamamoto, 2003).

    (hydrosol) .

    , (salt)

    , NaBH4 .

    ,

    (aggregation) .

    , (capping material) (Olenin, 2008; Si, 2007).

    (HCHO), (NaBH4), (citrate)

    , (PA), (PVA),

    (PVP) (PEG) .

    (SDS) . /, Klebsiella pneumoniae

    .

    , ,

    ,

    , ( , 2009).

    . PVP

    , ,

  • 195

    1234567891011121314

    Silver nanoparticlesSingle-walled carbon nanotubes (SWCNTs)Multi-walled carbon nanotubes (MWCNTs)Fullerenes (C60)Iron nanoparticlesCarbon blackTitanium dioxideAluminum oxideCerium oxideZinc oxideSilicon dioxidePolystyreneDendrimersNanoclays

    OECD

    (a) PVP (b) PVP

    : (2009).

    (PVP) . , (DLS) ; , (TEM) .

    Dp.57.1nm I

    g

    R

    w

    :--::;;-:-(---Q

    z

    g

    Dp.5 om g

    m

    m

    m

    :--:iic--

    (-a--

    ]

    -z

    -o. --

    . 0

    di:uutter (U l)

    ----.'

    -

    --.

    "- ~

    -~

    I

  • 196 49(2010)

    ( , 2009).

    .

    , OECD , ,

    , , (Scientific Committee on Emerging and

    Newly Identified Health Risks, 2006). ,

    , .

    , ,

    (Yoon et al., 2004).

    .

    , ,

    . 100

    . ,

    , . 2000

    . 2000

    . ,

    . , , , ,

    , .

    . , ,

    , , ,

    .

    . 100nm 1

    , 100nm~1

    30% (Hewett, 1995). , 100

    .

    ,

    (Yoon et al., 2004).

    . 100nm~1

    , 100nm 1

    .

  • 197

    Fullerene , , , , IT

    , ,

    , , , , ,

    , , , , ,

    , , , , ,

    , , MRI , , , ,

    , , , ,

    ,

    , , , , ,

    , ,

    , , ( ), ,

    , ,

    , (), , (),

    , ,

    , ,

    , , , ,

    , , , , ,

    .

    ' 1

    g

    // '1

    () ~

    g I I

  • 198 49(2010)

    : Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR), 2006.

    .

    ,

    . ,

    .

    . ,

    . ,

    . Ryman-Rasmussen (2006)

    .

    , , ,

    . ,

    .

    .

    1.000

    0.800

    I o6OO

    gg 04OO

    0.200

    0.000 0.01 0.1 1.0 10.0

    Pacle Diameter (microns)

  • 199

    .

    , -

    . , ,

    , , . ,

    OECD () .

    , , , , , ,

    .

    1)

    ,

    , . Kreyling (2002)

    ,

    . , Elder (2006)

    (olfactory bundle)

    . ,

    (Nurkiewicz et al., 2008). ,

    , , , , ,

    .

    2)

    Donaldson (2002)

    . , ,

    . , (broncho-alveolar fluid, BAL)

    (Shvedova et al., 2007).

    3)

    DNA ,

    (Li et al., 2007). ,

    . In vitro ,

    , - (Cunningham, 2007).

  • 200 49(2010)

    4)

    (Takagi et al., 2008). ,

    , (granuloma),1) (fibrosis) ,

    . ,

    (Muller et al., 2008).

    5)

    (Nurkiewicz et al., 2008).

    (Radomski et al., 2005).

    , ,

    .

    , ,

    , . ,

    , , ,

    .

    , , ,

    , ,

    ,

    . , ,

    , ,

    .

    ,

    . (nominal

    concentration) , ,

    ,

    . ,

    .

    1) ) .

  • 201

    .

    1)

    ,

    . ,

    . ,

    . OECD (WPMN)

    . OECD

    .

    , .

    100nm .

    .

    . ,

    . ,

    ,

    .

    2) ()

    ,

    , .

    ,

    . , (, )

    . fullerene

    ,

    , .

    , , , .

    ,

    .

    ,

  • 202 49(2010)

    (Physical-Chemical Properties and Material Characterization)

    /(Agglomeration/aggregation) (Water solubility) (Crystalline phase)(Dustiness)(Crystallite size)TEM (Representative TEM picture(s)) (Particle size distribution)(Specific surface area) / (Zeta potentiall; surface charge) (Surface chemistry, where appropriate) (Photocatalytic activity) (Pour density)(Porosity)/ (Octanol-water partition coefficient, where relevant) (Redox potential) (Radical formation potential)

    (Environmental Fate)

    (Dispersion stability in water) (Biotic degradability)(Ready biodegradability) (Simulation testing on ultimate degradation in surface water)(Soil simulation testing) (Sediment simulation testing) (Sewage treatment simulation testing) (Identification of degradation product(s)) ( Further testing of degradation product(s) as required) (Abiotic degradability and fate) (Hydrolysis, for surface modified nanomaterials)-(Adsorption-desorption) (Adsorption to soil or sediment) (Bioaccumulation potential)

    (Environmental Toxicology)

    / (Effects on pelagic species; short term/long term) / (Effects on sediment species; short term/long term)/ (Effects on soil species; short term/long term) (Effects on terrestrial species) (Effects on microorganisms)

    (Mammalian Toxicology)

    (Pharmacokinetics; ADME) (Acute toxicity)(Repeated dose toxicity)(Chronic toxicity)(Reproductive toxicity)(Developmental toxicity)(Genetic toxicity)

    : OECD, GUIDANCE MANUAL FOR THE TESTING OF MANUFACTURED NANOMATERIALS: OECD SPONSORSHIP PROGRAMME; FIRST REVISION, ENV/JM/MONO(2009) 20/REV, 2010.

  • 203

    .

    ,

    .

    ,

    .

    . ,

    ,

    . ,

    .

    ,

    . , , ,

    , , .

    .

    1)

    .

    .

    , QA/QC .

    2) .

    , (, ,

    , (, , ), ) .

    3)

    . ,

    , . ,

    .

    4)

    . .

    , ,

    .

    5) - (quantitative

  • 204 49(2010)

    structure-toxicity relationship, QSTR) .

    , . ,

    . ,

    , , ,

    .

    .

    .

    , QSTR

    .

    , . ,

    "

    , ,

    .

    ,

    . -

    , , 1

    .

    ,

    .

    , . ,

    , , ,

    - ,

    . ,

    ,

    .

    , 2009, , , 12(3): 98-107.

    , 2009,

    , , 12(2): 59-73.

  • 205

    Cunningham, M.J., 2007, Genecellular interactions of nanomaterials: genotoxicity to genomics. In:

    N.A. Monteiro-Riviere and C.L. Tran, Editors, Nanotoxicology Characterization, Dosing and

    Health Effects, Informa healthcare, New York, USA.

    Donaldson, K., D. Brown, A. Clouter, R. Duffin, W. MacNee, L. Renwick, V. Stone, 2002, The

    pulmonary toxicology of ultrafine particles, J. Aerosol Med., 15: 213-220.

    Elder, A., R. Gelein, V. Silva, T. Feikert, L. Opanashuk, J. Carter, R. Potter, A. Maynard, Y. Ito, J.

    Finkelstein, G. Oberdrster, 2006, Translocation of inhaled ultrafine manganese oxide particles

    to the central nervous system, Environ. Health Persp., 114: 1172-1178.

    Hewett, P., 1995, The particle size distribution, density and specific surface are of welding fumes

    from SMAW and GMAW mild and stainless steel consumables, American Industrial Hygiene

    Association Journal, 56(2): 128-135.

    Khanna, P., D. Kulkarni, R. Beri, 2008, Synthesis and characterization of myristic acid capped silver

    nanoparticles, J. Nanoparticle Research, 10: 1059-1062.

    Kreyling, W.G., M. Semmler, F. Erbe, P. Mayer, S. Takenaka, H. Schulz, G. Oberdrster, A.

    Ziesenis, 2002, Translocation of ultrafine insoluble iridium particles from lung epithelium to

    extrapulmonary organs is size dependent but very low, J. Toxicol. Environ. Health, Part A. 65:

    1513-1530.

    Li, W.X., J.Y. Xu, X.Q. Cai, R.L. Liu, Y.J. Li, Q.F. Zhao, Q.N. Li, 2007, Comparative study of

    pathological lesions induced by multiwalled carbon nanotubes in lungs of mice by intratracheal

    instillation and inhalation, Environ. Toxicol., 22(4): 415-421.

    Muller, J., I. Decordier, P.H. Hoet, N. Lombaert, L. Thomassen, F. Huaux, D. Lison, M.

    Kirsch-Volders, 2008, Clastogenic and aneugenic effects of multi-wall carbon nanotubes in

    epithelial cells, Carcinogenesis, 29: 427-433.

    Nurkiewicz, T.R., D.W. Porter, A.F. Hubbs, J.L. Cumpston, B.T. Chen, D.G. Frazer, V. Castranova,

    2008, Nanoparticle inhalation augments particle-dependent systemic microvascular dysfunction,

    Particle and Fibre Toxicology, 5: 1-12.

    Olenin A.Y., Y.A. Krutyakov, A.A. Kudrinskii, G.V. Lisichkin, 2008, Formation of surface layers on

    silver nanoparticles in aqueous and water-organic media, Colloid J, 70: 71-6.

    Radomski, A., P. Jurasz, D. Alonso-Escolano, M. Drews, M. Morandi, T. Malinski, M.W. Radomski,

    2005, Nanoparticle-induced platelet aggregation and vascular thrombosis, Brit. J. Pharmacol.,

    146(6): 882-893.

    Ryman-Rasmussen, J.P., J.E. Riviere, N.A. Monteiro-Riviere, 2006, Penetration of intact skin by

    quantum dots with diverse physicochemical properties, Toxicol. Sci., 91(1): 159-165.

  • 206 49(2010)

    Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR), The

    appropriateness of existing methodologies to assess the potential risks associated with engineered

    and adventitious products of nanotechnologies (2006).

    Shvedova, A.A., T. Sager, A.R. Murray, E. Kisin, D.W. Porter, S.S. Leonard et al., 2007, Critical

    issues in the evaluation of possible adverse pulmonary effects resulting from airborne

    nanoparticles. In: N.A. Monteiro-Riviere and C.L. Tran, Editors, Nanotoxicology

    Characterization, Dosing and Health Effects, Informa Healthcare, New York, USA.

    Si S, T.K. Mandal, 2007, Tryptophan-based peptides to synthesize gold and silver nanoparticles: a

    mechanistic and kinetic study, Chem Eur J, 13: 3160-8.

    Takagi, A., A. Hirose, T. Nishimura, N. Fukumori, A. Ogata, N. Ohashi, S. Kitajima, J. Kanno, 2008,

    Induction of mesothelioma in p53+/- mouse by intraperitoneal application of multi-wall carbon

    nanotube, J. Toxicol. Sci., 33(1): 105-116.

    Yamamoto, M., M. Nakamoto, 2003, Novel Preparation of Monodispersed Silver Nanoparticles Via

    Amine Adducts Derived from Insoluble Silver Myristate in Tertiary Alkylamine, J. Mat. Chem.,

    13: 2064-65.

    Yoon, C.S., 2004, Welding fume and others from welding processes, Korean Journal of

    Environmental Health, 30(4): 320-328.

    : . . . . . .